Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A simple, affordable fix for a serious problem: a randomized trial in Uganda found that giving children under 5 with sickle cell anemia 20 mg of zinc daily cut overall infection rates by 38% and severe bacterial infections by two-thirds. No adverse events requiring treatment discontinuation were reported, making this a potentially game-changing, low-cost intervention for a vulnerable population worldwide.
A randomized trial out of Uganda has found that daily zinc supplementation at 20 mg significantly reduces infection rates in young children with sickle cell anemia (SCA) — and the results are striking. Over six months, children receiving zinc had 80 infections compared to 124 in the placebo group, translating to a 38% lower infection rate. Severe bacterial infections dropped by an impressive two-thirds.
The trial enrolled 100 children aged 12–59 months with confirmed SCA at Jinja Regional Referral Hospital. All participants received standard care — including hydroxyurea, penicillin prophylaxis, folic acid, and malaria prevention — on top of either zinc or placebo. Zinc deficiency, which is common in children with SCA globally (affecting 44–57% even in North America), is thought to drive elevated infection risk, making supplementation a logical and low-cost target.
By the Numbers:
Why it matters: Sickle cell anemia disproportionately affects children in low-resource settings, where infection is a leading cause of death. A safe, inexpensive intervention like zinc supplementation — if confirmed in larger trials — could be rapidly deployed across diverse health systems globally.
